Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.

Garcia-Alfonso, PilarMunoz Martin, Andres J.Jimenez-Castro, JeronimoJimenez-Fonseca, PaulaPericay, CarlesLongo, FedericoReyna, CarmenArgiles, GuillemGonzalez Astorga, BeatrizJose Gomez-Reina, MariaRuiz Casado, AnaRodriguez-Salas, NuriaLopez-Lopez, RafaelCarmona Bayonas, AlbertoConde-Herrero, VeronicaAranda, Enrique2025-01-072025-01-072021-05-200732-183Xhttps://hdl.handle.net/10668/25274enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.conference outputopen access10.1200/JCO.2021.39.15_suppl.e155561527-7755https://europepmc.org/articles/pmc8468101?pdf=render708120301221